Doctors Chinnaiyan, Sawyers and the members of their Dream Team will focus on patients with metastatic prostate cancer. First, the team will implement a multi-institutional study that systematically evaluates patients enrolling in four clinical trials for novel drugs for CRPC at five leading clinical centers.
They will identify predictors of why some patients respond to these therapies, as well as predictors of resistance to these therapies. The study will capture a molecular snapshot of a patient’s cancer and incorporate this information into the clinical trials. It will also enable a framework that will facilitate progress toward a personalized approach for evaluating new drugs and treating patients with prostate cancer.
The delivery of clinically valuable information based on the analyses of each patient’s tumor will improve the lives of patients with prostate cancer. While state-of-the-art technology in DNA sequencing has dramatically accelerated biomedical research, translation into a clinical setting has numerous barriers that limit the potential benefits.
This multi-disciplinary, multi-institutional effort establishes a framework for translating research into precision prostate cancer medicine for patient care.
Watch a short video in which the Prostate Dream Team leaders
Chinnaiyan and Sawyers talk about the science behind their project:
How do I participate?
Men with metastatic hormone resistant prostate cancer may be eligible to participate in the Dream Team “Precision Therapy for Advanced Prostate Cancer” clinical trial program. Those men interested in this program should provide their information by clicking on the "Pre-registration Form" below.